Biogen
BIIB
Market cap $23.3B

159.99 USD

-4.90

2.97%

At close Nov 15, 4:00 PM EST

After hours

159.99

+0.00

0.00%

1 day

-2.97%

5 days

-8.01%

1 month

-16.48%

3 months

-20.65%

6 months

-32.01%

Year to date

-40.24%

1 year

-30.33%

5 years

-43.32%

10 years

-47.10%

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Employees: 7,570

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,704 funds

0

Analysts bullish %

of 19 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2.05% less ownership

Funds ownership: 89.1% [Q2] → 87.05% (-2.05%) [Q3]

5% less funds holding

Funds holding: 921 [Q2] → 873 (-48) [Q3]

19% less capital invested

Capital invested by funds: $30.1B [Q2] → $24.4B (-$5.63B) [Q3]

25% less call options, than puts

Call options by funds: $213M | Put options by funds: $282M

27% less funds holding in top 10

Funds holding in top 10: 11 [Q2] → 8 (-3) [Q3]

28% less repeat investments, than reductions

Existing positions increased: 258 | Existing positions reduced: 360

33% less first-time investments, than exits

New positions opened: 96 | Existing positions closed: 144

See Fund Rankings

Research analyst outlook

19 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$180

13%

upside

Avg. target

$253

58%

upside

High target

$300

88%

upside

19 analyst ratings

13 positive

68%

6 neutral

32%

0 negative

0%

Baird Brian Skorney 52% 1-year accuracy 11 / 21 met price target	88%upside $300	Outperform Maintained	15 Nov 2024
Citigroup Geoff Meacham 42% 1-year accuracy 10 / 24 met price target	19%upside $190	Neutral Initiated	14 Nov 2024
JP Morgan Chris Schott 29% 1-year accuracy 5 / 17 met price target	31%upside $210	Neutral Maintained	4 Nov 2024
Oppenheimer Jay Olson 29% 1-year accuracy 15 / 51 met price target	59%upside $255	Outperform Maintained	31 Oct 2024
Barclays Carter Gould 37% 1-year accuracy 14 / 38 met price target	13%upside $180	Equal-Weight Maintained	31 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 32 articles about BIIB published over the past 30 days

Zacks Investment Research

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

5 Healthcare Stocks to Buy in a Beaten-Up Sector

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.

5 Healthcare Stocks to Buy in a Beaten-Up Sector

Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug

Biogen's stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.

Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab as a treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (Early Alzheimer's disease) who are apolipoprotein E ε4 (ApoE ε4)* non-carriers or heterozygotes with confirmed amyloid pathology.1 Eisai had requested a re-examination of the prior negative opinion adopted by the CHMP in July 2024. In accordance with European Medicines Agency regulatory process, the European Commission is expected to make a final decision on the marketing authorization application (MAA) of lecanemab based on the CHMP recommendation within 67 days of receipt of CHMP opinion.2

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment.

EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen

Zacks Investment Research

Here's Why Biogen Inc. (BIIB) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Biogen Inc. (BIIB) is a Strong Value Stock

Zacks Investment Research

BIIB vs. MYGN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors a better bang for their buck right now?

BIIB vs. MYGN: Which Stock Is the Better Value Option?

Zacks Investment Research

Are Investors Undervaluing Biogen (BIIB) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Biogen (BIIB) Right Now?

Zacks Investment Research

Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Biogen (BIIB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Biogen reported its Q3 earnings yesterday, October 30. Revenue of $2.5bn was reported and non-GAAP EPS of $4.08. Growth was generally flat or declining for many key assets, with the performance of AD drug Leqembi especially underwhelming.

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

See News Rankings

Charts implemented using Lightweight Charts™